GlassScriptPhysician profile
Ann P Zilliox
NPI 1841284650
$2,220.43
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $387 · 2021: $594 · 2022: $529 · 2023: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $383.96 | 2019-2023 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $256.31 | 2020-2023 | Takhzyro, Cuvitru |
| Glaxosmithkline, LLC. | $240.01 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $165.87 | 2019-2023 | Dupixent |
| Genzyme Corporation | $151.25 | 2021-2023 | |
| Kaleo, INC. | $138.18 | 2020-2023 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $106.94 | 2019-2023 | Tezspire |
| Pfizer INC. | $105.37 | 2021 | |
| Pharming Healthcare, INC. | $104.08 | 2020-2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $103.43 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $76.54 | 2021-2023 | Orladeyo |
| Genentech USA, INC. | $59.40 | 2022-2023 | Xolair |
| Incyte Corporation | $45.05 | 2022-2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $43.77 | 2019-2023 | |
| Phadia US INC. | $38.74 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $36.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.44 | 2020 | |
| Boston Scientific Corporation | $25.14 | 2019 | |
| Shire North American Group INC | $24.90 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $19.54 | 2020 | |
| Sanofi Pasteur INC. | $16.59 | 2023 | |
| Merck Sharp & Dohme LLC | $15.44 | 2021 | |
| Bio Products Laboratory USA, INC. | $12.19 | 2019 | |
| Greer Laboratories, INC. | $11.57 | 2019 | |
| Alk-Abello, INC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Zilliox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.